Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study

BACKGROUND: Lung cancer is the fourth most common cancer in Brazil. In the 2000s, better understanding of molecular pathways led to development of epidermal growth factor receptor (EGFR)-targeted treatments that have improved outcomes. However, these treatments are unavailable in most Brazilian publ...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguiar, Pedro, Barreto, Carmelia Maria Noia, Roitberg, Felipe, Lopes, Gilberto, del Giglio, Auro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Paulista de Medicina - APM 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754282/
https://www.ncbi.nlm.nih.gov/pubmed/32159636
http://dx.doi.org/10.1590/1516-3180.2018.0256170919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754282/
https://www.ncbi.nlm.nih.gov/pubmed/32159636
http://dx.doi.org/10.1590/1516-3180.2018.0256170919

Ejemplares similares